InMed Pharmaceuticals Inc. Income Statement
INM|4 years of annual SEC 10-K data (FY2022-FY2025)
Line items include revenue, cost of goods sold, gross profit, operating expenses, interest, taxes, and net income with per-share data across 4 fiscal years. All figures from audited SEC 10-K filings.
InMed Pharmaceuticals Inc. reported $5M in revenue and $8M in net loss for FY2025. Revenue has grown at a 61.6% compound annual rate over the past 3 years.
Based on SEC 10-K filings.
Key Data Points
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
| Item | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $4.6M | $4.1M | $1.1M | $1.1M |
| Cost of Revenue | $3.5M | $2.7M | $545.9K | $545.9K |
| Gross Profit | $1.1M | $1.4M | $543.5K | $543.5K |
| SG&A Expense | $5.8M | $5.8M | $6.9M | $4.5M |
| R&D Expense | $3.2M | $3.7M | $7.3M | $5.3M |
| Operating Income | - | - | -$18.6M | -$10.2M |
| Interest Expense | - | - | - | -$360.4K |
| Income Tax | $7.1K | $13.1K | $13.1K | - |
| Net Income | -$7.7M | -$7.9M | -$18.6M | -$10.2M |
| EPS (Basic) | -$20.14 | -$3.25 | -$33.17 | -$37.96 |
| EPS (Diluted) | -$20.14 | -$3.25 | -$33.17 | -$37.96 |
| Shares Outstanding | 445.9K | 3.3M | 650.7K | 322.0K |
| Gross Margin | 23.9% | 33.9% | 49.9% | 49.9% |
| Operating Margin | - | - | -1707.3% | -936.6% |
| Profit Margin | -166.9% | -192.2% | -1707.3% | -936.6% |